{"id":456710,"date":"2021-03-12T07:13:26","date_gmt":"2021-03-12T12:13:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456710"},"modified":"2021-03-12T07:13:26","modified_gmt":"2021-03-12T12:13:26","slug":"crinetics-pharmaceuticals-showcasing-breadth-of-pipeline-at-endo-2021-with-presentations-on-three-clinical-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-showcasing-breadth-of-pipeline-at-endo-2021-with-presentations-on-three-clinical-programs\/","title":{"rendered":"Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs"},"content":{"rendered":"
\n

\n – Details of New Paltusotine Tablet Formulation to be Unveiled –<\/em>
\n \n <\/p>\n

\n – Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing\u2019s Disease Selected for Oral and Late-breaking Presentations –<\/em>\n <\/p>\n

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) — \u00a0Crinetics Pharmaceuticals, Inc.<\/a> (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced upcoming oral and poster presentations at the Endocrine Society\u2019s annual ENDO 2021 congress. In addition to a poster summarizing the company\u2019s previously announced ACROBAT Phase 2 results of paltusotine<\/a> for the treatment of acromegaly, Crinetics will provide details of the improved tablet formulation of paltusotine that the company plans to advance into Phase 3 studies. Preclinical evidence supporting the company\u2019s development of its selective somatostatin receptor type 5 (SST5) agonist, CRN04777, for the treatment of congenital hyperinsulinism<\/a> was selected for a late-breaking e-poster presentation. An oral presentation will also be given on the preclinical studies of CRN04894, the company\u2019s lead adrenocorticotropic hormone (ACTH) antagonist<\/a> for the treatment of diseases associated with excess ACTH such as congenital adrenal hyperplasia (CAH) and Cushing\u2019s disease.<\/p>\n

The poster and oral presentations will be made available on the Crinetics website following the conclusion of the congress. For ENDO attendees, Crinetics staff will also be available to address questions and discuss pipeline programs in the virtual exhibit hall.<\/p>\n

\n March 20, 2021, 11:00 a.m. eastern time<\/u>
\n
Session P15
Bench to Bedside: Novel Mechanisms in Diabetes and Metabolism<\/p>\n